Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease.

Von Willebrand disease (VWD) is an inherited bleeding disorder characterized by incomplete penetrance and variable expressivity. We evaluated a 24-member pedigree with VWD type 2 caused by a T>G mutation at position 3911 that predicts a methionine to arginine (M1304R) change in the platelet-binding A1 domain of von Willebrand factor (VWF). This mutation manifests as an autosomal-dominant trait, with clinical and biochemical phenotypic variability among affected individuals, including differences in bleeding tendency and VWF quantity, activity, and multimer pattern. Sequencing of all VWF coding regions in 3 affected individuals did not identify additional mutations. When expressed in heterologous cells, M1304R was secreted in lower quantities, failed to drive formation of storage granules, and was defective in multimerization and platelet binding. When cotransfected in equal quantities with the wild-type complementary DNA, the mutant complementary DNA depressed VWF secretion, although multimerization was only mildly affected. A llama nanobody (AU/VWFa-11) that detects the mutant A1 domain demonstrated highly variable binding to VWF from different affected members, indicating that the VWF contained different percentages of mutant monomers in different individuals. Thus, the observed variability in VWD phenotypes could in part be determined by the extent of mutant monomer incorporation in the final multimer structure of plasma VWF.

[1]  J. Di Paola,et al.  Variable bleeding phenotype in an Amish pedigree with von Willebrand disease , 2016, American journal of hematology.

[2]  J. Di Paola,et al.  Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF. , 2016, Thrombosis research.

[3]  R. Schneppenheim,et al.  von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein , 2011, Journal of thrombosis and haemostasis : JTH.

[4]  A. Bertomoro,et al.  An apparently silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease , 2011, Haematologica.

[5]  R. Koenen,et al.  CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment , 2011, Journal of thrombosis and haemostasis : JTH.

[6]  D. Hampshire,et al.  Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort , 2010, Haematologica.

[7]  D. Hampshire,et al.  von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels , 2010, Journal of thrombosis and haemostasis : JTH.

[8]  B. Coller,et al.  ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders , 2010, Journal of thrombosis and haemostasis : JTH.

[9]  R. Hoffmann,et al.  Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. , 2010, Blood.

[10]  K. Broman,et al.  Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice. , 2009, Blood.

[11]  P. Mannucci,et al.  Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. , 2009, Blood.

[12]  P. D. de Groot,et al.  The presence of active von Willebrand factor under various pathological conditions , 2007, Current opinion in hematology.

[13]  J. Moake,et al.  Conformational stability and domain unfolding of the Von Willebrand factor A domains. , 2007, Journal of molecular biology.

[14]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[15]  P. D. de Groot,et al.  A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. , 2005, Blood.

[16]  S. Lethagen,et al.  A comparative in vitro evaluation of six von Willebrand factor concentrates , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  A. Parodi,et al.  Quality control and protein folding in the secretory pathway. , 2003, Annual review of cell and developmental biology.

[18]  D. Ginsburg,et al.  Getting at the Variable Expressivity of Von Willebrand Disease , 2001, Thrombosis and Haemostasis.

[19]  P. Harvey,et al.  A single nucleotide polymorphism at nucleotide −1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels , 2000, British journal of haematology.

[20]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[21]  B. Lämmle,et al.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. , 1996, Blood.

[22]  J. Lavergne,et al.  Duplication of a methionine within the glycoprotein Ib binding domain of von Willebrand factor detected by denaturing gradient gel electrophoresis in a patient with type IIB von Willebrand disease. , 1991, Blood.

[23]  T. Mayadas,et al.  von Willebrand Factor Biosynthesis and Processing a , 1991, Annals of the New York Academy of Sciences.

[24]  M. L. Le Beau,et al.  Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. , 1991, Biochemistry.

[25]  J M Sorace,et al.  Structure of the gene for human von Willebrand factor. , 1989, The Journal of biological chemistry.

[26]  A. Federici,et al.  Gene deletions correlate with the development of alloantibodies in von Willebrand disease. , 1987, The Journal of clinical investigation.

[27]  H. Pannekoek,et al.  Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene , 1985, Nucleic Acids Res..

[28]  S. Latt,et al.  Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. , 1985, Science.

[29]  E. Jaffe,et al.  Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. , 1977, The Journal of clinical investigation.

[30]  E. Jaffe,et al.  Synthesis of antihemophilic factor antigen by cultured human endothelial cells. , 1973, The Journal of clinical investigation.

[31]  Hajime Sato,et al.  Alleles responsible for ABO phenotype-genotype discrepancy and alleles in individuals with a weak expression of A or B antigens. , 2004, Journal of forensic sciences.

[32]  B. Evatt,et al.  Screening questions to identify women with von Willebrand disease. , 2002, Journal of the American Medical Women's Association.

[33]  D. Ginsburg,et al.  Von Willebrand disease. , 2008, Pediatric clinics of North America.

[34]  C. Abildgaard,et al.  Serial studies in von Willebrand's disease: variability versus "variants". , 1980, Blood.